AbbVie Inc. (ABBV)

89.50
NYSE : Health Technology
Prev Close 87.20
Day Low/High 86.92 / 89.79
52 Wk Low/High 77.50 / 125.86
Avg Volume 6.79M
Exchange NYSE
Shares Outstanding 1.50B
Market Cap 131.17B
EPS 3.30
P/E Ratio 18.09
Div & Yield 4.28 (4.20%)

Latest News

Flexible, Patient Fed: Cramer's 'Mad Money' Recap

Flexible, Patient Fed: Cramer's 'Mad Money' Recap

Jim Cramer talks about the Fed, and outlines your game plan.

Qualcomm, Momo, Ciena: 'Mad Money' Lightning Round

Qualcomm, Momo, Ciena: 'Mad Money' Lightning Round

Jim Cramer weighs in on Qualcomm, Momo, Ciena, AbbVie, LM Ericsson and more.

Keep an Eye on Earnings: Cramer's 'Mad Money' Recap (Thursday 1/3/19)

Keep an Eye on Earnings: Cramer's 'Mad Money' Recap (Thursday 1/3/19)

Jim Cramer says a trade deal could help, but what matters after today is earnings -- and how bad the shortfalls will be.

Jim Cramer: The Long-Awaited Drug Company Consolidation Has Begun

Jim Cramer: The Long-Awaited Drug Company Consolidation Has Begun

And it is happening not a moment too soon.

AbbVie And Tizona Therapeutics Announce Strategic Collaboration To Develop First-in-Class Immunotherapy For Cancer Targeting CD39

AbbVie And Tizona Therapeutics Announce Strategic Collaboration To Develop First-in-Class Immunotherapy For Cancer Targeting CD39

- Initiation of clinical studies with TTX-030 is targeted in Q1 2019

AbbVie To Host Fourth-Quarter And Full-Year 2018 Earnings Conference Call

AbbVie To Host Fourth-Quarter And Full-Year 2018 Earnings Conference Call

NORTH CHICAGO, Ill., Jan.

3 Key Bear Market Rules, 5 Bargain Buys and a Monthly Dividend Portfolio

3 Key Bear Market Rules, 5 Bargain Buys and a Monthly Dividend Portfolio

Dow Theory presents tips for surviving a bear market, some top year-end stock bargains and a simple strategy for monthly income.

AbbVie: The Perfect Stock for High Yield and Growth

ABBV offers an ideal mix of growth, value and income.

AbbVie Submits New Drug Application To U.S. FDA And Marketing Authorization Application To EMA For Upadacitinib For Treatment Of Adults With Moderate To Severe Rheumatoid Arthritis

AbbVie Submits New Drug Application To U.S. FDA And Marketing Authorization Application To EMA For Upadacitinib For Treatment Of Adults With Moderate To Severe Rheumatoid Arthritis

- Regulatory applications supported by robust SELECT Phase 3 program evaluating more than 4,000 patients with moderate to severe rheumatoid arthritis[1-5]

AbbVie To Present At The 37th Annual J.P. Morgan Healthcare Conference

AbbVie To Present At The 37th Annual J.P. Morgan Healthcare Conference

NORTH CHICAGO, Ill., Dec.

AbbVie Announces Executive Leadership Changes

AbbVie Announces Executive Leadership Changes

NORTH CHICAGO, Ill., Dec.

AbbVie Announces $5 Billion Increase To Stock Repurchase Program

AbbVie Announces $5 Billion Increase To Stock Repurchase Program

NORTH CHICAGO, Ill., Dec.

How to Invest in Cannabis - In Its Many Forms

How to Invest in Cannabis - In Its Many Forms

As cannabis becomes more and more legal, investors have started to wonder what that means for them.

Phase 3 Trial Of Rova-T As Second-line Therapy For Advanced Small-Cell Lung Cancer (TAHOE STUDY) Halted

Phase 3 Trial Of Rova-T As Second-line Therapy For Advanced Small-Cell Lung Cancer (TAHOE STUDY) Halted

- Independent Data Monitoring Committee responsible for ongoing review of study data recommended enrollment be stopped

IMBRUVICA® (ibrutinib) Combination Regimen Significantly Improved Survival Versus The Chemoimmunotherapy FCR (Fludarabine, Cyclophosphamide And Rituximab) In Previously Untreated And Younger Chronic Lymphocytic Leukemia (CLL) Patients; Late-Breaking Phase 3 Data At ASH 2018

IMBRUVICA® (ibrutinib) Combination Regimen Significantly Improved Survival Versus The Chemoimmunotherapy FCR (Fludarabine, Cyclophosphamide And Rituximab) In Previously Untreated And Younger Chronic Lymphocytic Leukemia (CLL) Patients; Late-Breaking Phase 3 Data At ASH 2018

- Results from this interim analysis showed ibrutinib plus rituximab prolonged progression-free survival (PFS) compared to a standard chemoimmunotherapy regimen of fludarabine, cyclophosphamide and rituximab (FCR) at nearly 3 years of follow-up (abstract #LBA-4)

IMBRUVICA® (ibrutinib) Phase 3 Combination Data With Obinutuzumab Finds Significant Improvement In Progression-Free Survival (PFS) Over Standard Chemoimmunotherapy Of Chlorambucil Plus Obinutuzumab For Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

IMBRUVICA® (ibrutinib) Phase 3 Combination Data With Obinutuzumab Finds Significant Improvement In Progression-Free Survival (PFS) Over Standard Chemoimmunotherapy Of Chlorambucil Plus Obinutuzumab For Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

- These data were included in the recent sNDA accepted by the U.S. FDA, which received Priority Review, and could lead to the first chemotherapy-free anti-CD20 combination approved for first-line CLL treatment

IMBRUVICA® (ibrutinib) Data In Chronic Lymphocytic Leukemia (CLL) Show Up To Seven Years Of Progression-free Survival (PFS) In 80 Percent Of Previously Untreated Patients, The Longest Follow-up For A Bruton's Tyrosine Kinase Inhibitor To Date

IMBRUVICA® (ibrutinib) Data In Chronic Lymphocytic Leukemia (CLL) Show Up To Seven Years Of Progression-free Survival (PFS) In 80 Percent Of Previously Untreated Patients, The Longest Follow-up For A Bruton's Tyrosine Kinase Inhibitor To Date

- With up to seven years of treatment, sustained PFS rates with ibrutinib in CLL/small lymphocytic lymphoma (SLL) at 80 percent for previously untreated patients

AbbVie Presents New Data From Phase 3 MURANO Trial Of VENCLEXTA®/VENCLYXTO® (venetoclax) In Combination With Rituximab In Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia Who Completed The Fixed Treatment Course

AbbVie Presents New Data From Phase 3 MURANO Trial Of VENCLEXTA®/VENCLYXTO® (venetoclax) In Combination With Rituximab In Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia Who Completed The Fixed Treatment Course

- The data demonstrated that VENCLEXTA®/VENCLYXTO® in combination with rituximab (VenR) reduced the risk of disease progression or death compared to a standard of care, bendamustine plus rituximab (BR), after a median three-year follow-up[1]

AbbVie Announces HUMIRA® (adalimumab) Global Patent License With Pfizer

AbbVie Announces HUMIRA® (adalimumab) Global Patent License With Pfizer

NORTH CHICAGO, Ill., Nov.

AbbVie Receives US FDA Accelerated Approval For VENCLEXTA® (venetoclax) For Treatment Of Newly-Diagnosed Acute Myeloid Leukemia Patients Ineligible For Intensive Chemotherapy

AbbVie Receives US FDA Accelerated Approval For VENCLEXTA® (venetoclax) For Treatment Of Newly-Diagnosed Acute Myeloid Leukemia Patients Ineligible For Intensive Chemotherapy

- Acute myeloid leukemia (AML) is one of the most aggressive blood cancers, with a very low survival rate and few options for patients who are ineligible for intensive chemotherapy[1,2]

AbbVie Presents Positive Phase 3 Data Demonstrating Investigational Elagolix Reduces Heavy Menstrual Bleeding In Women With Uterine Fibroids At 2018 AAGL Global Congress

AbbVie Presents Positive Phase 3 Data Demonstrating Investigational Elagolix Reduces Heavy Menstrual Bleeding In Women With Uterine Fibroids At 2018 AAGL Global Congress

-Elagolix, in combination with add-back therapy, achieved statistically significant reduction in heavy menstrual bleeding associated with uterine fibroids compared to placebo

AbbVie's MAVYRET™ (glecaprevir/pibrentasvir) Shows High Virologic Cure* Rates In Treatment-Naïve Hepatitis C Patients With Compensated Cirrhosis

AbbVie's MAVYRET™ (glecaprevir/pibrentasvir) Shows High Virologic Cure* Rates In Treatment-Naïve Hepatitis C Patients With Compensated Cirrhosis

- EXPEDITION-8 is the first Phase 3b study evaluating 8 weeks of MAVYRET™ in treatment-naïve chronic hepatitis C virus (HCV)-infected patients with compensated cirrhosis across all major genotypes (GT1-6)[1]

AbbVie To Present At The Evercore ISI Conference

AbbVie To Present At The Evercore ISI Conference

NORTH CHICAGO, Ill., Nov.

Hagens Berman Reminds AbbVie (NYSE: ABBV) Investors Of Ongoing Investigation Of AbbVie's Humira Sales Practices

Hagens Berman Reminds AbbVie (NYSE: ABBV) Investors Of Ongoing Investigation Of AbbVie's Humira Sales Practices

SAN FRANCISCO, Nov. 9, 2018 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP reminds investors in AbbVie Inc.

AbbVie Characterizes Evolving Hepatitis C (HCV) Patient Landscape In The United States Using Comprehensive Dataset

AbbVie Characterizes Evolving Hepatitis C (HCV) Patient Landscape In The United States Using Comprehensive Dataset

- New MappingHepC.com website provides HCV community an easily accessible source of chronic HCV epidemiology data

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In AbbVie Inc. Of Class Action Lawsuit And Upcoming Deadline - ABBV

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In AbbVie Inc. Of Class Action Lawsuit And Upcoming Deadline - ABBV

NEW YORK, Nov. 7, 2018 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against AbbVie Inc.

AbbVie Announces HUMIRA® (adalimumab) Global Patent License With Momenta

AbbVie Announces HUMIRA® (adalimumab) Global Patent License With Momenta

NORTH CHICAGO, Ill., Nov.

TheStreet Quant Rating: B- (Buy)